Study reports epigenetic age acceleration in brains of patients with structural epilepsy

A retrospective cross-sectional study published in EBioMedicine reports that drug-resistant structural epilepsy is associated with a median of 7.3 years of epigenetic age acceleration in brain tissue, establishing tissue-specific biological aging as a potential pathway for therapeutic targeting.

Researchers evaluated DNA-methylation-based epigenetic clocks in brain and blood samples from 324 unique individuals with structural or genetic epilepsy and 65 non-epilepsy controls.

The study found a consistent median epigenetic age acceleration of 7.3 years (p < 0.0001) in brain tissues across structural lesion types, which was most pronounced in ganglioglioma (+10 years) and focal cortical dysplasia (+5.6 years).

In blood samples, overall epigenetic age acceleration was not statistically significant after covariate adjustment (median +0.7 years, p = 0.20), except for a cohort with focal cortical dysplasia (+2.3 years, p < 0.05).

Using a drug-naïve somatic mTOR-activation mouse model, researchers observed that brain-specific epigenetic age acceleration and shortened relative telomere length occurred during the pre-seizure latency phase, suggesting biological aging can precede overt epilepsy symptoms.

This research provides direct molecular evidence that epilepsy is linked to localized biological aging in the brain rather than a uniform systemic aging process.

The manifestation of accelerated epigenetic aging and telomere shortening prior to seizure onset in mouse models suggests that biological aging is an intrinsic, early component of the pathology rather than simply a consequence of chronic seizures or medical therapies.

The involvement of somatic mTOR pathway activation in driving both biological age acceleration and structural epilepsy highlights shared upstream pathways that could serve as novel drug targets.

The clear discrepancy between brain and blood age acceleration indicates that developers of longevity therapeutics must prioritize tissue-specific targeting and delivery systems over systemic interventions for neurological conditions.

The validation of epigenetic clocks in diseased clinical brain tissues supports the clinical utility of methylation-based biomarkers for evaluating localized therapeutic efficacy and disease progression.

Preclinical and clinical investigations evaluating whether epigenetic editing or mTOR-pathway inhibitors can successfully halt or reverse the tissue-specific epigenetic age acceleration associated with structural epilepsy.